Posts

Parkinson’s disease and the Parkinsonisms (ISSN 2753-8176 (online))

Parkinson’s disease and the Parkinsonisms (ISSN 2753-8176 (online)) 1.Ana Pedro 1.Gwyntwr1386 Health & Social Care, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com Parkinson’s Disease was first described by James Parkinson in 1817. Idiopathic Parkinson's disease is caused by a loss of nerve cells in the part of the brain called the substantia nigra which produce dopamine. Dopamine acts as a messenger between the parts of the brain and nervous system that help control and co-ordinate body movements. The loss of these nerve cells is a slow process and Parkinson's disease symptoms' usually start to develop when around 50% of the nerve cell activity in the substantia nigra have been lost (1). Parkinson's disease is a common condition in elderly people. About 137,000 people were living with Parkinson's disease in the UK. The prevalence rate was 286.5 per 100,000 person-years (2). The symptoms of Parkinson's disease ...
Post a Comment
Read more

Music therapy, dementia and Alzheimer’s disease – a review (ISSN 2753-8176 (online))

Music therapy, dementia and Alzheimer’s disease – a review (ISSN 2753-8176 (online)) 1. Ana Pedro 1.Gwyntwr1386 Health & Social Care, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com Music shows a positive effect on cognitive functioning and music-making has a small but statistically significant effect on cognitive functioning for older adults with probable mild cognitive impairment (MCI) or dementia (1). Music therapy (MT) positively affects mood, neuropsychiatric behaviour, apathy, communication and physical functions for dementia improving symptomatology. Also, behavioural/psychological symptoms improve in severe dementia, and memory and verbal fluency improve in mild Alzheimer's disease. Both active (playing music) and receptive (listening to music) methods are used for dementia (2). Also, MT besides improving patients' symptomatology also helps with caregivers' burden(3). Also, music based interventions (MBIs) consisting o...
Post a Comment
Read more

Bilingual/ monolingual individuals and relationship with Dementia and Parkinson’s disease progression – brief opinion (ISSN 2753-8176 (online))

Bilingual/ monolingual individuals and relationship with Dementia and Parkinson’s disease progression – brief opinion (ISSN 2753-8176 (online)) 1. Ana Pedro 1.Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com One of the most challenging aspects of living with moderate dementia is the loss of language skills, in particularly for bilingual individuals, who have difficulty in maintaining fluency in more than one language (1-3). The loss of second language skills is a strong predictor for decreased well-being in people living in care homes, due to communication barriers between residents and carers, which may result, for example, in being unable to obtain help to self-care, as well as in social isolation. Evidence indicates that bilingual individuals develop Alzheimer's disease (AD) later than monolinguals, showing relative strengths in the domain of inhibition and response conflict (1-3). Bilinguals also may retain an ad...
Post a Comment
Read more

CPAX and POC troponin testing device for patients with heart disease and cognitive impairment – NHS Innovation Service (ISSN 2753-8176 (online))

CPAX and POC troponin testing device for patients with heart disease and cognitive impairment – NHS Innovation Service (ISSN 2753-8176 (online)) 1. Ana Pedro 1.Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com We concluded that most MCA users are elderly patients. Also, most of the patients suffer of combined cardiovascular disease. We intend to do an assessment of feasibility about providing a new online clinical delivery and treatment monitoring service for the NHS based on the CpaX medication management program from Jones Healthcare group in Canada coupled with a POC troponin test in helping patients with cognitive impairment and/or heart disease taking their medication properly. Is your innovation relevant to any of the following areas? Independence and prevention Digitalising the system Improving system flow Operational excellence Patient activation and self-care Patient safety and quality improvement Workf...
Post a Comment
Read more

Coupling Gwyntwr1386 laboratory testing to NHS App (ISSN 2753-8176 (online))

Coupling Gwyntwr1386 laboratory testing to NHS App (ISSN 2753-8176 (online)) 1. Ana Pedro 1.Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com Description of innovation The innovation is that as for example prescriptions are available at NHS App, we could also make available at NHS App the patients clinical lab tests requests and results working with Gwyntwr1386 pharmacy, so that we could very easily request and perform clinical lab tests and get the results straight away so that the GP could easily decide about booking another appointment or issuing a prescription, through the NHS App. Select all the categories that can be used to describe your innovation In vitro diagnostic Pharmaceutical Digital (including apps, platforms, software) Personal protective equipment (PPE) Models of care and clinical pathways Data and monitoring Select a primary category to describe your innovation Digital (including apps,...
Post a Comment
Read more

A Plasma-based Apolipoprotein ELISA Assay to detect Neuropsychiatric Disorders – Project Proposal (ISSN 2753-8176 (online))

A Plasma-based Apolipoprotein ELISA Assay to detect Neuropsychiatric Disorders – Project Proposal (ISSN 2753-8176 (online)) 1. Ana Pedro 1.Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com Protocol title A Plasma-based Apolipoprotein ELISA Assay to detect Neuropsychiatric Disorders Protocol identifying number Version 0.1 Date 14/07/2024 Name and address of the Sponsor and monitor Name and title of the person(s) authorised to sign the protocol and the protocol amendment(s) for the Sponsor Ana Pedro, MPHARM, PhD Name and title of the investigator(s) who is (are) responsible for conducting the study, and the address and telephone number(s) of the study site(s). Ana Pedro, MPHARM, PhD Name(s) and address(es) of the clinical laboratory(ies) and other medical and/or technical department(s) and/or institutions involved in the study Background Information Neuropsychiatric disorders (NDs) are a...
Post a Comment
Read more

A Plasma-based Apolipoprotein and p-tau Elisa Assay to detect Alzheimer’s and differentiate from other dementia types for the NHS (ISSN 2753-8176 (online))

Image
A Plasma-based Apolipoprotein and p-tau Elisa Assay to detect Alzheimer’s and differentiate from other dementia types for the NHS (ISSN 2753-8176 (online)) 1. Ana Pedro 1.Gwyntwr1386 Pharmacy, Regus Chester Business Park, Heronsway, Chester, CH49QR, UK. info@gwyntwr1386.com A - Please select the innovation sector In-vitro diagnostic B- Please provide a brief description of the innovation including relevant disease area(s) and target patient and service user population(s) Apolipoproteins are “any of various proteins that combine with a lipid to form a lipoprotein, such as HDL and LDL”, or “The protein components of lipoproteins, which remain after the lipids to which the proteins are bound have been removed”(1). Apolipoproteins are reported to be linked to many neurodegenerative disorders. APOE plays a role in many brain disorders, including Alzheimer’s disease, mild cognitive impairment, multiple sclerosis, traumatic brain injury, and maybe in more some others ...
Post a Comment
Read more